TargetBeta
P2RY12
purinergic receptor P2Y12 · also P2Y12, SP1999, HORK3 · P2Y receptors
3 programs in company-led studies act on P2RY12, from 3 companies: 1 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Ticagrelorrule | AstraZeneca | phase 4 | 471 running | – | ChEMBL |
| Clopidogrelrule | Sanofi | phase 4 | 710 running | – | ChEMBL |
| selatogrelrule | Viatris | phase 3 | 111 running | – | ChEMBL |
Conditions their studies are in
- Coronary Artery Disease, 3 programs
- Acute Coronary Syndrome, 2 programs
- Anemia, Sickle Cell, 1 program
- Cardiovascular Diseases, 1 program
- Diabetes Mellitus, Type 2, 1 program
- Heart Defects, Congenital, 1 program
- Ischemic Attack, Transient, 1 program
- Myocardial Infarction, 1 program
- Vaso-Occlusive Crises, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 31, 2027Ticagrelor · AstraZeneca · phase 4 · NCT07438886
- Jul 2027selatogrel · Viatris · phase 3 · NCT04957719
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.